



# *Corporate Overview*



---

## *Experts in Maximizing Value in Dermatology*

---

- **Commercial Dermatology and Podiatry company with proven expertise in maximizing brands**
  - Proven commercial expertise in maximizing brands anchored by more than 35 years of experience and relationships in Dermatology & Podiatry
    - Marketed brands for the most common diseases in Dermatology & Podiatry with wide breadth and depth across these markets
- **Dedicated management team with a proven track record of generating sales and increasing profits**
  - Commercial expertise enhanced by development expertise
    - Xepi® (ozenoxacin cream), a topical impetigo treatment licensed from Ferrer; sold to Cutanea Life Sciences (2018)
    - MM36 (difamilast), a topical treatment for atopic dermatitis acquired by Acrotech Biopharma, a subsidiary of Aurobindo (2021)
    - Acquired >15 brands, 3 companies and achieved 8 ANDA and 2 NDA approvals
  - Executive Leadership
    - David Addis, Chief Executive Officer
    - Brent Lenczycki, Chief Financial Officer
    - Donna Heren, VP, Regulatory Affairs & Quality Assurance
- **Acquired by Eurofarma November, 2022**

# EUROFARMA AT GLANCE

One of the Leading LatAm Pharma Companies

**+50** Years  
of history



Products in the pharma'  
**main segments**



**+12,000 employees**



**#1** prescription  
pharma in Brazil<sup>1</sup>



**#2** pharma  
in LatAm<sup>2</sup>



## LEADERSHIP

**R\$2.4 bi**  
2022 Adjusted EBITDA<sup>3</sup>

**25% CAGR**  
2017-2022



## COMPETITIVENESS

**#1** sales force  
+4,000 salespeople

**29.6%**  
2022 Adjusted EBITDA margin



## EXPANSION

**22 countries**  
presence

**100%**  
LatAm coverage



## INNOVATION

**+290 projects**  
on pipeline by 2028

**R\$591 mm**  
R&D Expenses in 2022  
**7.4%** of net revenue



## RECOGNITION

**18 years** Great Place to  
Work

**4x** Sustainability Ranking<sup>4</sup>  
(the only pharma company)

(1) Eurofarma, Momenta and Supera; Close-up Dec/22; (2) Dec/22 Retail Reais PPP; (3) Adjusted for R&D expenses; (4) Guia Exame Award.

# Medimetriks: Poised for Growth

1

## Strong Commercial Platform

### Foundation for Growth Through Licensing and Acquisition

- Commercial experts in maximizing brand value in key markets
  - Company revenue growing to \$15MM
- Robust portfolio of brands promoted through experienced national sales force
  - Dedicated field force growing to 35 professional sales representatives that support highest potential US markets
- Senior Management has strong, long-standing relationships with Dermatology and Podiatry Key Opinion Leaders and High Volume Prescribers

2

## Development Expertise & Lifecycle Management

### Robust Development Capabilities

- Led development programs for 2 NCEs:
  - Supported Grupo Ferrer in the FDA approval of Xepi® (ozenoxacin), a novel topical antibiotic for impetigo
  - Developed MM36 (difamilast), a topical PDE4 inhibitor for atopic dermatitis, through Phase 3 initiation
- Significant lifecycle management and line extension opportunities exist in the current brand portfolio

3

## Eurofarma Acquisition

### Committed to Establishing a Leading US Pharmaceutical Company

- Eurofarma is well-capitalized and focused on making an impact in the US market
- Eurofarma has a presence in 22 Latin American countries, is the largest pharmaceutical company in Brazil on a prescription basis, and is the second largest pharmaceutical company in Latin America
- Eurofarma's goal is to expand US operations through acquisition and licensing, expanding its Dermatology presence in the near term, and to additional specialties in the long term



# Medimetriks Core Brand Growth Drivers

- Marketed brands for the treatment of common dermatologic diseases, including acne, rosacea, psoriasis, atopic dermatitis and nail dystrophy

SKIN & SCALP DERMATOSES	
<b><i>Clodan.</i></b>	(clobetasol propionate)
<b>Ketodan®</b>	(ketoconazole foam)
NEO-SYNALAR®	(fluocinolone acetonide/neomycin)
SYNALAR®	(fluocinolone acetonide)
<b><i>Tovet.</i></b>	(clobetasol foam)
ONYCHODYSTROPHY	
<b><i>Genadur.</i></b>	(hydrosoluble nail lacquer)

ACNE & ROSACEA	
<b><i>Clindacin® P &amp; ETZ</i></b>	(clindamycin phosphate)
<b>Neuac®</b>	(clindamycin/benzoyl peroxide)
<b>Sumadan®</b>	(sodium sulfacetamide/sulfur)